Physician profile
Denise J Force
NPI 1770067522
$71,199.79
in general payments reported to CMS, 2019-2025
22 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $383 · 2023: $5,752 · 2024: $44K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,696.45 |
| Food and Beverage | $738.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $69,765.61 | 2023-2025 | Minimed 780g |
| Novo Nordisk INC | $217.63 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $200.76 | 2021-2024 | Trelegy Ellipta |
| Abbott Laboratories | $191.36 | 2021-2022 | |
| Corcept Therapeutics | $157.73 | 2021-2024 | Korlym |
| Lilly USA, LLC | $109.73 | 2021-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $89.32 | 2021-2025 | Recorlev |
| Ibsa Pharma INC. | $73.89 | 2021-2024 | Tirosint, Licart, Tirosint |
| Abbvie INC. | $65.37 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.40 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $30.68 | 2024-2025 | Isturisa, Signifor Lar |
| Sanofi-Aventis U.S. LLC | $29.78 | 2021 | |
| Amgen INC. | $28.70 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.44 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.99 | 2021-2025 | Jardiance |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $27.86 | 2022 | |
| Amarin Pharma, INC. | $27.27 | 2021 | |
| Phathom Pharmaceuticals, INC. | $21.76 | 2025 | Voquezna |
| Sequel Med Tech, LLC | $16.87 | 2025 | Twiist |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.58 | 2025 | Caplyta |
| Becton, Dickinson and Company | $14.46 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Force listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.